Biomarkers of Atrial Fibrillation Complicated With Stroke Based on Proteomics and Metabolomics

January 8, 2022 updated by: Yue LI
Thrombus shedding in patients with atrial fibrillation (AF) can lead to cerebral artery embolism. Stroke caused by AF is very dangerous, which not only threatens the life of patients, but also seriously affects the quality of life. This study aims to explore the biomarkers of stroke in patients with AF by integrating proteomics and metabolomics data, and establish the network relationship of stroke in patients with AF, so as to reveal the molecular mechanism of stroke in patients with AF.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Heilongjiang
      • Harbin, Heilongjiang, China, 150001

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The blood samples of patients with AF and patients with AF complicated with stroke were taken. The supernatant was centrifuged and put into - 80 ℃ refrigerator for storage.

Description

Inclusion Criteria:

  1. Age 18 years or above
  2. Admission with atrial fibrillation or clinic visit for atrial fibrillation
  3. Receive routine anticoagulant therapy;
  4. Signing the consent form

Exclusion Criteria:

  1. Pregnant women;
  2. Lactating women;
  3. Severe mitral stenosis;
  4. Severe impairment of liver function;
  5. Severe renal insufficiency;
  6. Thyroid dysfunction requiring treatment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
AF
Patients with AF
Diagnostic test: Proteomics
Proteomic data were obtained by LC-MS/MS Analysis-DIA platform.
Diagnostic test: Metabolomics
Metabolomic data were obtained by UPLC-QTOF/MS platform.
AF and stroke
Patients with AF complicated with stroke
Diagnostic test: Proteomics
Proteomic data were obtained by LC-MS/MS Analysis-DIA platform.
Diagnostic test: Metabolomics
Metabolomic data were obtained by UPLC-QTOF/MS platform.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Biomarkers of atrial fibrillation complicated with stroke based on proteomics and metabolomics
Time Frame: 1 day
By combining proteomics and metabolomics data, the investigators were able to identify the common pathways involved in AF with stroke.
1 day

Secondary Outcome Measures

Outcome Measure
Time Frame
Quantitative changes of individual metabolites and proteins were calculated and graphed using the KEGG mapping tools.
Time Frame: 1 day
1 day
By combining proteomics and metabolomics data, the investigators were able to identify the common pathways involved in AF with stroke.
Time Frame: 1 day
1 day
All of the omics data were used to compare proteins/enzymes with metabolic pathways.
Time Frame: 1 day
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Yue LI

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 20, 2021

Primary Completion (Anticipated)

December 31, 2023

Study Completion (Anticipated)

December 31, 2023

Study Registration Dates

First Submitted

December 20, 2021

First Submitted That Met QC Criteria

December 20, 2021

First Posted (Actual)

January 6, 2022

Study Record Updates

Last Update Posted (Actual)

January 25, 2022

Last Update Submitted That Met QC Criteria

January 8, 2022

Last Verified

January 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AF and stroke 1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

Clinical Trials on Proteomics

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe